Logo: Unknown author Unknown author, Public domain, via Wikimedia Commons6
American agriculture company
Corteva, Inc. (also known as Corteva Agriscience) is an American company devoted to products for seeds and crop protection, including herbicides, insecticides, fungicides, and biologicals (natural herbicides) that are sold in 110 countries. The company's name combines "cor" (Latin for "heart") with "teva" (the Hebrew word for nature). It is headquartered in Indianapolis, Indiana.3 Its chief executive is Chuck Magro (since 2021).1 It employed about 21,000 people in 2022.1 Its revenue was $17.4 billion in 2022.1 It is part of DowDuPont.1 Its shares trade on NYSE under the symbol CTVA.1Wikipedia text CC BY-SA 4.0
$12.82down 0.06 (0.43%)Price as of Oct 16, 2026 at 19:58 UTC
Corteva, Inc. (also known as Corteva Agriscience) is an American company devoted to products for seeds and crop protection, including herbicides, insecticides, fungicides, and biologicals (natural herbicides) that are sold in 110 countries. The company's name combines "cor" (Latin for "heart") with "teva" (the Hebrew word for nature). It is headquartered in Indianapolis, Indiana. Its primary brand is Pioneer Hi-Bred International.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Revenue1516$6.4B in Q2 FY2026+30% since Q1 FY2026Net income1516$1.2B in Q2 FY2026+61% since Q1 FY2026
Every line of the income statement as filed: the last 3 fiscal years, latest first.10
Period ending
2025-12-31
2024-12-31
2023-12-31
Net Sales
$17.4B
$16.9B
$17.2B
Cost of Goods Sold
$9.2B
$9.5B
$9.9B
Research and Development Expense
$1.5B
$1.4B
$1.3B
Selling, General and Administrative Expense
$3.5B
$3.2B
$3.2B
Amortization of Intangibles
$644.0M
$685.0M
$683.0M
Restructuring and asset related charges - net
$146.0M
$288.0M
$336.0M
Business Separation Costs
$35.0M
$0
$0
Other income (expense) - net
-$570.0M
-$300.0M
-$448.0M
Interest Expense
$180.0M
$233.0M
$233.0M
Income (loss) from continuing operations before income taxes
$1.7B
$1.3B
$1.1B
Provision for (benefit from) income taxes on continuing operations
$484.0M
$412.0M
$152.0M
Income (loss) from continuing operations after income taxes
$1.2B
$863.0M
$941.0M
Income (loss) from discontinued operations after income taxes
-$99.0M
$56.0M
-$194.0M
Net income (loss)
$1.1B
$919.0M
$747.0M
Net income (loss) attributable to noncontrolling interests
$11.0M
$12.0M
$12.0M
Net Income (Loss) attributable to Company
$1.1B
$907.0M
$735.0M
Basic earnings (loss) per share of common stock from continuing operations
$2
$1
$1
Basic earnings (loss) per share of common stock from discontinued operations
-$0
$0
-$0
Basic earnings (loss) per share of common stock
$1.60
$1.31
$1.04
Diluted earnings (loss) per share of common stock from continuing operations
$2
$1
$1
Diluted earnings (loss) per share of common stock from discontinued operations
-$0
$0
-$0
Diluted earnings (loss) per share of common stock
$1.60
$1.30
$1.03
No quarter-by-quarter statement was filed.
Total assets171112131410$42.8B in 2025+1% since 2019Shareholders’ equity171112131410$24.1B in 2025−1% since 2019Cash171112131410$4.5B in 2025+156% since 2019
Total assets1516$41.6B in Q2 FY2026−3% since Q1 FY2025Shareholders’ equity1516$25.2B in Q2 FY2026+4% since Q1 FY2025Cash1516$2.4B in Q2 FY2026−48% since Q1 FY2025
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 6 quarters (quarterly), latest first.10
Period ending
2026-01-31
2025-12-31
2024-12-31
2023-12-31
2022-12-31
Cash and Cash Equivalents
$4.5B
$3.1B
Marketable Securities
$9.0M
$63.0M
Accounts and notes receivable - net
$6.4B
$5.7B
Inventories
$5.7B
$5.4B
Other current assets
$767.0M
$820.0M
Total current assets
$17.3B
$15.1B
Investments in nonconsolidated affiliates
$160.0M
$134.0M
Property, Plant and Equipment
$9.6B
$9.1B
Less: Accumulated Depreciation
$5.3B
$5.0B
Net Property, Plant and Equipment
$4.2B
$4.1B
$4.3B
Goodwill
$10.5B
$10.4B
$10.6B
Other intangible assets
$8.3B
$8.9B
Deferred Income Taxes
$320.0M
$401.0M
Other Assets
$2.0B
$1.8B
Total Assets
$42.8B
$40.8B
Short-term borrowings and finance lease obligations
$894.0M
$750.0M
Accounts Payable
$4.4B
$4.0B
Income Taxes Payable
$155.0M
$207.0M
Deferred Revenue
$3.6B
$3.3B
Accrued and other current liabilities
$3.1B
$2.1B
Total current liabilities
$12.1B
$10.4B
Long-term Debt
$1.7B
$2.0B
Deferred Income Tax Liabilities
$251.0M
$478.0M
Pension and other post employment benefits - noncurrent
$2.4B
$2.3B
Other noncurrent obligations
$2.0B
$1.7B
Total Noncurrent Liabilities
$6.3B
$6.4B
Common Stock, Shares, Issued
672.2M shares
685.6M shares
701.3M shares
713.4M shares
Common stock
$7.0M
$7.0M
Additional Paid in Capital
$27.0B
$27.2B
Retained earnings (accumulated deficit)
-$67.0M
$55.0M
Accumulated other comprehensive income (loss)
-$2.8B
-$3.5B
Total stockholders' equity attributable to the company
$24.1B
$23.8B
Noncontrolling Interests
$242.0M
$241.0M
Total Equity
$24.4B
$24.0B
$25.3B
$25.5B
Total Liabilities and Equity
$42.8B
$40.8B
Common Stock, Par Value
$0.01
$0.01
$0.01
Common Stock, Shares Authorized
1.7B shares
1.7B shares
Common Stock, Shares, Outstanding
672.2M shares
685.6M shares
701.3M shares
713.4M shares
Period ending
2026-01-31
2025-12-31
2024-12-31
2023-12-31
2022-12-31
2019-05-31
Cash and Cash Equivalents
$4.5B
$3.1B
Marketable Securities
$9.0M
$63.0M
Accounts and notes receivable - net
$6.4B
$5.7B
Inventories
$5.7B
$5.4B
Other current assets
$767.0M
$820.0M
Total current assets
$17.3B
$15.1B
Investments in nonconsolidated affiliates
$160.0M
$134.0M
Property, Plant and Equipment
$9.6B
$9.1B
Less: Accumulated Depreciation
$5.3B
$5.0B
Net Property, Plant and Equipment
$4.2B
$4.1B
$4.3B
Goodwill
$10.5B
$10.4B
$10.6B
Other intangible assets
$8.3B
$8.9B
Deferred Income Taxes
$320.0M
$401.0M
Other Assets
$2.0B
$1.8B
Total Assets
$42.8B
$40.8B
Short-term borrowings and finance lease obligations
$894.0M
$750.0M
Accounts Payable
$4.4B
$4.0B
Income Taxes Payable
$155.0M
$207.0M
Deferred Revenue
$3.6B
$3.3B
Accrued and other current liabilities
$3.1B
$2.1B
Total current liabilities
$12.1B
$10.4B
Long-term Debt
$1.7B
$2.0B
Deferred Income Tax Liabilities
$251.0M
$478.0M
Pension and other post employment benefits - noncurrent
$2.4B
$2.3B
Other noncurrent obligations
$2.0B
$1.7B
Total Noncurrent Liabilities
$6.3B
$6.4B
Common Stock, Shares, Issued
672.2M shares
685.6M shares
701.3M shares
713.4M shares
Common stock
$7.0M
$7.0M
Additional Paid in Capital
$27.0B
$27.2B
Retained earnings (accumulated deficit)
-$67.0M
$55.0M
Accumulated other comprehensive income (loss)
-$2.8B
-$3.5B
Total stockholders' equity attributable to the company
$24.1B
$23.8B
Noncontrolling Interests
$242.0M
$241.0M
Total Equity
$24.4B
$24.0B
$25.3B
$25.5B
Total Liabilities and Equity
$42.8B
$40.8B
Common Stock, Par Value
$0.01
$0.01
$0.01
$0.01
Common Stock, Shares Authorized
1.7B shares
1.7B shares
Common Stock, Shares, Outstanding
672.2M shares
685.6M shares
701.3M shares
713.4M shares
Cash from operations1112131410$3.4B in 2025+218% since 2019Dividends paid1112131410$475.0M in 2025Share buybacks1112131410$1.1B in 2025+4184% since 2019
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.10
Period ending
2025-12-31
2024-12-31
2023-12-31
Net income (loss)
$1.1B
$919.0M
$747.0M
(Income) Loss from Discontinued Operations, after income taxes
$99.0M
-$56.0M
$194.0M
Depreciation and amortization
$1.2B
$1.2B
$1.2B
Provision for (benefit from) deferred income tax
-$41.0M
-$365.0M
-$438.0M
Net periodic pension and OPEB (benefit) cost, net
$36.0M
$160.0M
$138.0M
Pension and OPEB contributions
-$136.0M
-$151.0M
-$149.0M
Net (gain) loss on sales of property, businesses, consolidated companies and investments
-$41.0M
-$17.0M
-$22.0M
Restructuring and Asset Related Charges - net
$146.0M
$288.0M
$336.0M
Other net loss
$545.0M
$383.0M
$578.0M
Accounts and Notes Receivable
-$261.0M
-$705.0M
$358.0M
Inventories
-$35.0M
$1.1B
$57.0M
Accounts Payable
$231.0M
-$115.0M
-$663.0M
Deferred Revenue
$270.0M
-$86.0M
-$11.0M
Other Assets and Liabilities
$336.0M
-$296.0M
-$527.0M
Cash Provided by (Used for) Operating Activities - Continuing Operations
$3.5B
$2.3B
$1.8B
Cash Provided by (Used for) Operating Activities - Discontinued Operations
-$51.0M
-$151.0M
-$40.0M
Cash provided by (used for) operating activities
$3.4B
$2.1B
$1.8B
Capital expenditures
-$591.0M
-$597.0M
-$595.0M
Proceeds from Sales of property, businesses, and consolidated companies - net of cash divested
$54.0M
$5.0M
$57.0M
Acquisitions of businesses - Net of Cash Acquired
$0
$0
-$1.5B
Investments in and loans to nonconsolidated affiliates
-$20.0M
-$7.0M
-$32.0M
Purchases of investments
$0
-$144.0M
-$148.0M
Proceeds from Sale and Maturities of Investments
$135.0M
$130.0M
$147.0M
Payments for (Proceeds from) Hedge, Investing Activities
-$83.0M
$63.0M
$42.0M
Other investing activities - net
-$38.0M
-$39.0M
-$2.0M
Cash provided by (used for) investing activities
-$543.0M
-$589.0M
-$2.0B
Net Change in borrowings (less than 90 days)
$0
$53.0M
-$6.0M
Proceeds from Debt
$1.7B
$3.1B
$3.4B
Payments on Debt
-$1.9B
-$2.9B
-$2.3B
Repurchase of Common Stock
-$1.1B
-$1.0B
-$756.0M
Proceeds from Exercise of Stock Options
$88.0M
$60.0M
$31.0M
Dividends Paid to stockholders
-$475.0M
-$458.0M
-$439.0M
Other financing activities, net
-$45.0M
-$32.0M
-$49.0M
Cash provided by (used for) financing activities
-$1.6B
-$1.2B
-$99.0M
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents
$84.0M
-$93.0M
-$143.0M
Increase (decrease) on cash, cash equivalents and restricted cash
Corteva sits at the top of its group. 217 entities, 70 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Corteva
Capital World InvestorsFiled SCHEDULE 13G/A on Corteva, latest Aug 12, 2026 (2 filings since May 14, 2026)
FMR LLCFiled SCHEDULE 13G on Corteva, latest May 6, 2026
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Corteva reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
The company operates out of its headquarters in Indianapolis, Indiana. It also maintains a global business center in Johnston, Iowa, for its Seed business. Its manufacturing, processing, marketing and research and development facilities, as well as regional purchasing offices and distribution centers, are located throughout the world. The company has 95 production sites in the following geographic regions:
Number of Sites
The rest of Item 2
Seed · Crop Protection · Total
North America 1 · 38 · 7 · 45
EMEA 2 · 12 · 9 · 21
Latin America · 8 · 13 · 21
Asia Pacific · 3 · 5 · 8
Total · 61 · 34 · 95
1. North America consists of U.S. & Canada.
2. Europe, Middle East, and Africa ("EMEA").
The company's principal sites include facilities which, in the opinion of management, are suitable and adequate for their use and have sufficient capacity for the company's current needs and expected near-term growth. Properties are either owned by the company or leased, in such cases typically under a long-term lease. No title examination of the properties has been made for the purpose of this report and certain properties are shared with other tenants under long-term leases.
After the merger of the Dow Chemical Company and DuPont to form DowDuPont in August 2017, Corteva was formed in March 2018 as a subsidiary handling the parent company's agriculture activities, which focused on seeds and crop protection. In June 2019, DowDuPont completed the corporate spin-off of the company and Corteva became a public company. Included in the spin-off was E. I. du Pont de Nemours and Company, the former corporate entity of DuPont which was designated as the predecessor to Corteva and was renamed to EIDP, Inc. in January 2023.
In March 2019, Corteva commissioned Charles River Laboratories to test its new fungicide on 36 beagles. Corteva argued that such testing is required by regulatory authorities but, after outrage from the Humane Society of the United States, the company agreed to stop the tests and release the animals to Michigan Humane for adoption.
In February 2020, Corteva ceased production of the pesticide chlorpyrifos due to declining sales after the product was linked to neurological problems in children and following bans in the European Union and some US states.
In March 2023, the company acquired Stoller Group, a maker of natural pesticides for $1.2 billion. It also acquired Symborg, an expert in microbiological technologies based in Murcia, Spain. This was part of an overall strategy to grow and strengthen an emerging biologicals product portfolio.
In November 2024, the company partnered with BP to develop a low carbon intensive bio-feedstock for the production of aviation biofuel. Also in November 2024, the company acquired the naming rights to the Indiana Farmers Coliseum at the Indiana State Fairgrounds. In 2025, the company introduced Forcivo, a fungicide for corn and soybeans containing flutriafol, azoxystrobin, and fluindapyr and targeting tar spot, southern rust, and frogeye leaf spot. In September 2025, the Wall Street Journal reported the company was exploring a breakup that would separate its seed and pesticide businesses. The company confirmed it planned to separate the businesses in October 2025. In May 2026, Corteva announced the name Vylor for its seed and genetics business.
In July 2020, a U.S. appeals court ruled that Corteva can continue to sell Enlist Duo, which contains glyphosate and a salt of 2,4-D and choline, after environmentalists attempted to block sales of the chemical due to its claimed negative effects on plants and wildlife. However, the court ruled that the U.S. Environmental Protection Agency properly relied on studies that showed that the volatility of 2,4-D choline salt will not cause unreasonable harm to the environment.
In August 2022, Bayer sued Corteva for breach of contractual obligations related to the development and commercialization of E3 soybeans. Corteva then sued Bayer, alleging that Bayer infringed upon its patents on a gene used in Enlist Corn, which is resistant to herbicides such as Roundup. In May 2025, the case was paused until the US Supreme Court considers whether to take up a separate patent-related case.
In September 2022, the Federal Trade Commission sued Syngenta and Corteva, challenging certain US-based discount programs that allegedly block and restrict generic competition from pesticide markets. In January 2024, a federal judge denied a motion to dismiss the lawsuit.
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
414 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 56 major events, 290 insider forms, 16 large holders, 32 other. The latest 20:
21 open-market trades by officers, directors and large owners since October 2021: 7 buys and 14 sales. Grants, option exercises and gifts are left out.
BlackRockSC 13G/A, 3 filings Feb 7, 2022 to Feb 13, 202479
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
AuditorPricewaterhouseCoopers LLP, Philadelphia, Pennsylvania PCAOB ID 238; it also attests to the company’s internal control over financial reporting18
From the cover page of the 10-K filed Feb 12, 2026 (Section 12(b) of the Exchange Act).18
Risk factors and legal proceedings
The risks Corteva names in Item 1A of its 10-K filed Feb 12, 2026: 28 risks under these headings, as written.18
Risks Related to Our Industry
Corteva may not be able to obtain or maintain the necessary regulatory approvals for some of its products, including its seed and crop protection products, which could restrict its ability to sell those products in some markets.
The successful development and commercialization of Corteva's pipeline products will be necessary for Corteva's growth.
The degree of public understanding and acceptance or perceived public acceptance of Corteva’s biotechnology and other agricultural products and technologies can affect Corteva’s sales and results of operations by affecting planting approvals, regulatory requirements and customer purchase decisions.
Corteva’s business is subject to various competition and antitrust, rules and regulations around the world, and as the size of its business grows, scrutiny of its business by legislators and regulators in these areas may intensify.
Changes in agricultural and related policies of governments and international organizations may prove unfavorable.
The costs of complying with evolving regulatory requirements could negatively impact Corteva’s business, results of operations and financial condition. Actual or alleged violations of environmental laws or permit requirements could result in restrictions or prohibitions on plant operations, substantial civil or criminal sanctions, as well as the assessment of strict liability and/or joint and several liability.
Climate change and unpredictable seasonal and weather factors could impact Corteva’s sales and earnings.
Corteva participates in an industry that is highly competitive and has undergone consolidation, which could increase competitive pressures.
Recent funding and staff reductions, including at the EPA, the USDA, the FDA and the U.S. Department of Health and Human Services ("HHS"), could hinder our ability to receive timely regulatory approvals.
Corteva’s sales to its customers may be adversely affected should a company successfully establish an intermediary platform for the sale of Corteva’s products or otherwise position itself between Corteva and its customers.
Risks Related to Our Operations
The other 18 risks
Our business, financial condition and results of operations could be materially affected by disruptions in the global economy caused by geopolitical and military conflicts.
Volatility in Corteva’s input costs, which include raw materials and production costs, could have a significant impact on Corteva’s business, results of operations and financial condition.
Corteva’s operations outside the United States are subject to risks and restrictions, which could negatively affect Corteva’s business, results of operations and financial condition.
Corteva’s business, results of operations and financial condition could be adversely affected by industrial espionage and other disruptions to its supply chain, information technology or network systems.
Corteva’s business, results of operations and financial condition could be adversely affected by environmental, litigation and other commitments and contingencies.
Corteva is dependent on its relationships or contracts with third parties with respect to certain of its raw materials or licenses and commercialization.
Corteva’s customers may be unable to pay their debts to Corteva, which could adversely affect Corteva’s results.
Failure to effectively manage acquisitions, divestitures, strategic investments, restructurings, cost savings initiatives and other portfolio actions may not have the results anticipated.
Corteva’s liquidity, business, results of operations and financial condition could be impaired if it is unable to raise capital through the capital markets or short-term debt borrowings.
Increases in pension and other post-employment benefit plan funding obligations may adversely affect Corteva’s results of operations, liquidity or financial condition.
Global or regional health pandemics or epidemics could negatively impact the company's business, financial condition and results of operations.
Sentiment towards sustainability matters could adversely affect our stock price, results of operations, and access to capital.
Risks Related to Our Intellectual Property
Enforcing Corteva’s intellectual property rights, or defending against intellectual property claims asserted by others, could materially affect Corteva’s business, results of operations and financial condition.
Corteva’s business may be adversely affected by the availability of counterfeit products.
Restrictions under the intellectual property cross-license agreements limit Corteva’s ability to develop and commercialize certain products and services and/or prosecute, maintain and enforce certain intellectual property.
Risks Related to the Corteva Separation
The Corteva Separation and related transactions may expose Corteva to potential liabilities arising out of state and federal fraudulent conveyance laws
The company is subject to continuing contingent tax-related liabilities of DowDuPont following the Distribution.
Risks related to our Proposed Separation
Corteva is subject to risks related to its plans to separate its seed and crop protection businesses in a spin-off that will result in two standalone public companies, including that the proposed separation may not be completed on the contemplated timeline or at all and may not achieve the intended benefits.
Legal proceedings
The company is subject to various legal proceedings, including, but not limited to, product liability, intellectual property, antitrust, commercial, property damage, personal injury, environmental and regulatory matters arising out of the normal course of its current businesses or legacy EIDP businesses unrelated to Corteva’s current businesses but allocated to Corteva as part of the Corteva Separation from DuPont.
Often these proceedings raise complex factual and legal issues, which are subject to risks and uncertainties and which could require significant amounts of the senior leadership team’s time. Litigation and other claims, along with regulatory proceedings, against the company could also materially adversely affect its operations, reputation, and/or result in the incurrence of unexpected expenses and liability. Even when the company believes liabilities are not expected to be material or the probability of loss or of an adverse unappealable final judgment is remote, the company may consider settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the company, including avoidance of future distraction and litigation defense cost, and its shareholders. Information regarding certain of these matters is set forth below and in Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.
Litigation related to Corteva’s current businesses
